Thailand

Thailand

The CDC trial in Thailand is examining the safety and efficacy of tenofovir. The study is being conducted in collaboration with the Bangkok Metropolitan Administration and the Thailand Ministry of Public Health and has enrolled 2,400 HIV-negative intravenous drug users (IDUs) — male and female — at 17 drug treatment clinics in Bangkok. Participants are recruited at the drug treatment clinics, at community outreach sites, and through a peer referral program.

Botswana

The Botswana study is examining the behavioral and clinical safety of tenofovir plus emtricitabine and adherence to the regimen. This trial began as a safety and efficacy trial, but key challenges — including lower than anticipated HIV incidence and retention rates in the trial population — meant that the trial would be unable to determine efficacy. However, the study will still examine critical questions related to safety and adherence that will help guide potential implementation of PrEP, should efficacy be demonstrated in other trials.

The trial is being conducted in collaboration with the Botswana government and enrolled 1,200 HIV-negative heterosexual men and women, ages 18 to 39, in the nation’s two largest cities, Gaborone and Francistown. Participants were recruited through a number of venues, including HIV voluntary counseling and testing centers, sexually transmitted disease (STD) and family planning clinics, youth organizations, and community events.